Get startedLog in
    Picture of Jenburkt Pharmaceuticals logo

    524731 — Jenburkt Pharmaceuticals Income Statement

    0.000.00%
    in flag iconLast trade - 00:00
    HealthcareAdventurousMicro CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Jenburkt Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

    2020
    March 31st
    2021
    March 31st
    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IAS
    IAS
    IAS
    IAS
    IAS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1,1891,0931,2401,3671,420
    Cost of Revenue
    Gross Profit8477849131,0221,101
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Other Operating Expenses
    Total Operating Expenses1,0149159861,0861,112
    Operating Profit174178254281308
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes211216299329352
    Provision for Income Taxes
    Net Income After Taxes149165223246260
    Net Income Before Extraordinary Items
    Net Income149165223246260
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income149165223246260
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS32.43648.355.758.9
    Dividends per Share